2022
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ, Leontiadis GI. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. The American Journal Of Gastroenterology 2022, 117: 542-558. PMID: 35297395, PMCID: PMC8966740, DOI: 10.14309/ajg.0000000000001627.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDirect oral anticoagulantsP2Y12 receptor inhibitorsAcute gastrointestinal bleedingProthrombin complex concentrateSecondary preventionAcetylsalicylic acidGastrointestinal bleedingPCC administrationReceptor inhibitorsTemporary interruptionEndoscopy settingTarget patientsGastroenterology Clinical Practice GuidelineFresh frozen plasma administrationAdministration of idarucizumabManagement of anticoagulantsDual antiplatelet therapyAcute GI bleedingGrading of RecommendationsClinical practice guidelinesFresh frozen plasmaAcute GIASA monotherapyPeriendoscopic managementAntiplatelet therapyAmerican College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ, Leontiadis GI. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Journal Of The Canadian Association Of Gastroenterology 2022, 5: 100-101. PMID: 35368325, PMCID: PMC8972207, DOI: 10.1093/jcag/gwac010.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDirect oral anticoagulantsAcute gastrointestinal bleedingProthrombin complex concentrateSecondary preventionAcetylsalicylic acidGastrointestinal bleedingPCC administrationReceptor inhibitorsTemporary interruptionEndoscopy settingTarget patientsGastroenterology Clinical Practice GuidelineFresh frozen plasma administrationAdministration of idarucizumabManagement of anticoagulantsDual antiplatelet therapyAcute GI bleedingGrading of RecommendationsClinical practice guidelinesFresh frozen plasmaAcute GIASA monotherapyPeriendoscopic managementAntiplatelet therapyGI bleeding
2021
Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗
Bittl JA, Laine L. Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy ∗. Journal Of The American College Of Cardiology 2021, 79: 129-131. PMID: 34752903, DOI: 10.1016/j.jacc.2021.10.027.Commentaries, Editorials and Letters
2016
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL, Investigators C. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. The American Journal Of Medicine 2016, 129: 1002-1005. PMID: 27143321, DOI: 10.1016/j.amjmed.2016.03.042.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapyProton pump inhibitorsAcute coronary syndromePercutaneous coronary interventionCardiovascular eventsCoronary syndromeCoronary interventionGastrointestinal eventsPercutaneous coronary intervention-treated patientsSafety of PPIsUnadjusted Cox proportional hazards modelCox proportional hazards modelDays of randomizationMajor cardiovascular eventsComposite cardiovascular eventsSubset of patientsSafety of omeprazoleProportional hazards modelGastroprotective strategiesMedian followPPI therapyAntiplatelet therapyFrequent indicationHazards modelPatientsProton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP, Investigators C. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Journal Of The American College Of Cardiology 2016, 67: 1661-1671. PMID: 27012778, DOI: 10.1016/j.jacc.2015.12.068.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinClopidogrelDose-Response Relationship, DrugDrug Therapy, CombinationDyspepsiaFemaleGastrointestinal HemorrhageHumansIntestinal ObstructionIntestinal PerforationMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationOmeprazolePainPeptic UlcerPlatelet Aggregation InhibitorsProspective StudiesProton Pump InhibitorsStrokeTiclopidineConceptsDual antiplatelet therapyLow-dose aspirinProton pump inhibitorsMajor adverse cardiac eventsAdverse cardiac eventsPPI therapyAntiplatelet therapyAspirin usersGastrointestinal eventsCardiac eventsGI eventsMeier estimatesArtery diseaseCardiovascular endpointsLow-dose aspirin usersPrimary cardiovascular endpointUpper GI eventsHigh-dose aspirinPeripheral artery diseasePercutaneous coronary interventionCoronary artery diseaseHigh rateAspirin groupBlinded gastroenterologistsAspirin dose
2010
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal Of Medicine 2010, 363: 1909-1917. PMID: 20925534, DOI: 10.1056/nejmoa1007964.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsDual antiplatelet therapyUpper gastrointestinal bleedingAntiplatelet therapyCardiovascular eventsGastrointestinal bleedingOvert upper gastrointestinal bleedingPrimary cardiovascular end pointEnd pointEvent ratesEfficacy of clopidogrelSymptomatic gastroduodenal ulcersCardiovascular end pointsComposite of deathNonfatal myocardial infarctionSerious adverse eventsCoronary artery diseaseHigh-risk subgroupsRisk of diarrheaCardiovascular causesGastrointestinal complicationsGastrointestinal eventsOccult bleedingAntithrombotic therapyAdverse events
2007
Evaluation of Proton Pump Inhibitor Use in Patients With Acute Coronary Syndromes Based on Risk Factors for Gastrointestinal Bleed
Schreiner GC, Laine L, Murphy SA, Cannon CP. Evaluation of Proton Pump Inhibitor Use in Patients With Acute Coronary Syndromes Based on Risk Factors for Gastrointestinal Bleed. Critical Pathways In Cardiology A Journal Of Evidence-Based Medicine 2007, 6: 169-172. PMID: 18091407, DOI: 10.1097/hpc.0b013e318159921e.Peer-Reviewed Original ResearchConceptsUse of PPIsAcute coronary syndromeProton pump inhibitorsGI risk factorsRisk factorsCoronary syndromeHigh GI risk patientsProton pump inhibitor useNonsteroidal anti-inflammatory agentsInfection Therapy-ThrombolysisLong-term bleedingPrior GI eventsDual antiplatelet therapyUse of anticoagulantsAnti-inflammatory agentsAtorvastatin EvaluationAntiplatelet therapyGastrointestinal bleedGastrointestinal bleedingGI bleedingGI eventsInhibitor useRisk patientsTrials databasesPump inhibitors